Shanghai Ruihongdi Medicine

Shanghai Ruihongdi Medicine is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics for autoimmune and inflammatory diseases. The company focuses on the development of highly selective kinase inhibitors, particularly targeting the Janus kinase (JAK) family and Tyrosine kinase 2 (TYK2). Its lead program, RHD-102, is a selective JAK3 inhibitor currently undergoing Phase 2 clinical trials for the treatment of alopecia areata. Additionally, the company is advancing RHD-001, a selective JAK1 inhibitor, and RHD-201, a TYK2 inhibitor, to address unmet needs in conditions such as atopic dermatitis and psoriasis. By utilizing its proprietary drug discovery platform, Shanghai Ruihongdi Medicine aims to optimize the safety and efficacy profiles of its candidates to provide next-generation treatments for chronic immune-mediated disorders.